title: Proteomics and the blood-brain barrier: how recent findings help drug development.
abstract: The drug discovery and development processes are divided into different stages separated by milestones to indicate that significant progress has been made and that certain criteria for target validation, hits, leads and candidate drugs have been met. Proteomics is a promising approach for the identification of protein targets and biochemical pathways involved in disease process and thus plays an important role in several stages of the drug development. The blood-brain barrier is considered as a major bottleneck when trying to target new compounds to treat neurodegenerative diseases. Based on the survey of recent findings and with a projection on expected improvements, this report attempt to address how proteomics participates in drug development.
authors.affiliation: a Laboratoire de la Barrière Hématoencéphalique (LBHE) , Univesrité d'Artois EA2465 , Lens , France.
authors.forename: Yannis
authors.initials: Y
authors.lastname: Karamanos
authors.affiliation: a Laboratoire de la Barrière Hématoencéphalique (LBHE) , Univesrité d'Artois EA2465 , Lens , France.
authors.forename: Gwënaël
authors.initials: G
authors.lastname: Pottiez
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D002199:Capillary Permeability; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D040901:Proteomics / Q000379:methods*
keywords: Blood–brain barrier; brain capillary endothelial cells; drug development; neurovascular unit; proteomics